Robi Chatterji, MD
Family Medicine · Enid, OKNPI 1750322459
Payments from drug & device makers
Across 266 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$652
- Merck$452
- AstraZeneca$434
- Amgen$414
- Johnson & Johnson$337
- Pfizer$313
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,113100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $652 |
| Merck | 29 | $452 |
| AstraZeneca | 30 | $434 |
| Amgen | 25 | $414 |
| Johnson & Johnson | 22 | $337 |
| Pfizer | 21 | $313 |
| Novo Nordisk | 17 | $277 |
| Boehringer Ingelheim | 17 | $276 |
| Sunovion Pharmaceuticals Inc. | 11 | $150 |
| Lilly USA, LLC | 10 | $148 |
| Biohaven Pharmaceuticals, Inc. | 7 | $110 |
| Novartis | 6 | $88 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Lundbeck LLC | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Eisai Inc. | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $29 |
| Mylan Specialty L.p. | 2 | $27 |
| Halozyme Inc | 1 | $19 |
| Avion Pharmaceuticals | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$4,127 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $151,557 |
| EliquisApixaban | 79 | $84,332 |
| XareltoRivaroxaban | 98 | $80,986 |
| JanuviaSitagliptin Phosphate | 92 | $76,182 |
| TrulicityDulaglutide | 63 | $65,401 |
| JardianceEmpagliflozin | 80 | $61,492 |
| AustedoDeutetrabenazine | 12 | $58,062 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 13 | $30,713 |
| LinzessLinaclotide | 48 | $27,441 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $26,018 |
| TradjentaLinagliptin | 24 | $23,247 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $21,485 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $15,101 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $14,492 |
| NuvigilArmodafinil | 12 | $12,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $277 | $161,558166 claims |
| MerckJanuvia, Janumet, Janumet Xr | $452 | $109,886140 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat | $276 | $109,487141 claims |
| Johnson & JohnsonXarelto, Invokana | $337 | $93,281110 claims |
| PfizerEliquis | $313 | $84,33279 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $148 | $77,48574 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $39 | $58,06212 claims |
| AbbVieLinzess | $652 | $27,44148 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $434 | $16,42134 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $12,00625 claims |
| Sanofi-aventis U.S. LLCAmbien | $12 | $7,60912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Enid
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.